Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age

BACKGROUND: IMPAACT P1066 is a Phase I/II open-label multicenter trial to evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of multiple raltegravir (RAL) formulations in human immunodeficiency virus (HIV)-infected youth. METHODS: Dose selection of the oral suspension formulation for...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Pediatric Infect Dis Soc
Main Authors: Nachman, Sharon, Alvero, Carmelita, Acosta, Edward P., Teppler, Hedy, Homony, Brenda, Graham, Bobbie, Fenton, Terence, Xu, Xia, Rizk, Matthew L., Spector, Stephen A., Frenkel, Lisa M., Worrell, Carol, Handelsman, Edward, Wiznia, Andrew
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2015
Assuntos:
ELECTRONIC ARTICLES
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4681385/
https://ncbi.nlm.nih.gov/pubmed/26582887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jpids/piu146
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares